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MONITORING, IDENTIFICATION AND INTERVENTION FOR METABOLIC 
DISORDERS IN VETERANS WITH PSYCHOTIC DISORDERS.  
Michael H. Swetye, Christopher B. Ruser, Mohini Ranganathan, and Robert M. 
Rohrbaugh. Department of Psychiatry, Veteran Affairs Connecticut Healthcare System, 
West Haven, CT.  
 
In light of growing evidence that certain antipsychotics may cause potentially life-
threatening metabolic side-effects, the purpose of this study was to determine how 
regularly mental health clinicians (MHCs) currently monitor and manage metabolic 
abnormalities in overweight and obese patients with psychotic disorders. We 
hypothesized that MHCs monitor, identify and intervene for metabolic abnormalities in 
their patients at significantly lower rates than primary care physicians (PCCs), and that 
such rates may jeopardize patient health.   
We performed a one-year cross-sectional medical record review of primary care 
and mental health routine outpatient visit notes from the West Haven Campus of the 
Veteran Affairs Connecticut Healthcare System. We reviewed the records of a cohort of 
123 veterans who met the following inclusion criteria: (1) primary diagnosis of 
schizophrenia or schizoaffective disorder; (2) at least one routine mental health visit at 
the West Haven VA facility between July 1, 2005 and June 30, 2006; and (3) overweight 




The 123 subjects were predominantly white and male (56% and 93%, 
respectively) with an average body mass index (BMI) of 32.4 (SD=5.4). 97% of subjects 
were taking an antipsychotic of some sort, and 85% were taking a second-generation 
antipsychotic.  
Zero diagnoses of metabolic syndrome and zero waist-size measurements were 
documented by PCCs or MHCs. The following differences in documentation were found 
between PCCs and MHCs, respectively: weight (85% vs. 11%; p<0.001); BMI (48% vs. 
0%; p<0.001); identified weight as an issue (45% vs. 28%; p<0.005); identified the link 
between antipsychotics and weight issues (10% vs. 12%; not significant); made diet and 
exercise recommendations (42% vs. 19%; p<0.001); ordered a weight-management 
referral (21% vs. 3%; p<0.001); ordered or considered ordering a change of antipsychotic 
medication or dose due to weight-related issues (6% vs. 3%; not significant). PCCs 
ordered laboratory tests at much higher rates than MHCs, including blood glucose, 
thyroid stimulating hormone, urinalysis, lipid panel, and hemoglobin A1C (differences 
were large and significant).  
We concluded that MHCs monitor, identify and intervene for metabolic 
abnormalities in their patients at significantly lower rates than PCCs, and that such rates 
are unacceptably low.  The problem is one of a systemic failure in quality control and 
may pose a danger to patients. We advocate a rapid organizational response and systemic 
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Historical Background: Metabolic Derangement, Psychotic Disorders, and 
Antipsychotics  
 
Well before the advent of antipsychotics there was a string of clinicians who had 
associated psychotic disorders with metabolic abnormalities. In 1904 Kraeplin described 
an association between weight gain and the regression of dementia praecox symptoms (1, 
2). In1926, Kasanin described an association between schizophrenia and elevated blood 
glucose (3). Kooy, writing in 1919, associated psychotic disorders with abnormal levels 
of blood glucose (4).  In 1947 Kryspin-Exner observed patients gaining weight as soon as 
or before symptoms improved (2, 5).  
Even in the antipsychotic era, some investigators have postulated that there are 
potentially drug-independent associations between schizophrenia and metabolic 
dysfunction (6). Furthermore, Brown et al. and others have shown that determining the 
causes of metabolic dysfunction in psychotic patients is complicated by the unhealthy 
lifestyle that is observed in many such patients, a finding that makes it more difficult to 
delineate drug-induced from disease or behavior-induced metabolic dysfunction in 
psychotic patients (7, 8). 
With the introduction of chlorpromazine into clinical practice by Smith-Kline and 
French in 1952 and the subsequent explosion of antipsychotic discovery and use, 
antipsychotics emerged as a potential cause of metabolic abnormalities in psychotically 




injected chlorpromazine with increased blood glucose levels (10). Then in 1960 Klett and 
Caffey associated weight gain with the clinical efficacy of phenothiazine derivatives (2, 
11). Singh et al. found similar associations in a study published in 1970 (2, 12).  
The first atypical antipsychotic, clozapine, became commercially available in 
Europe in 1971 (13). By the mid-1990’s several atypical antipsychotics had been 
developed and were being prescribed by physicians (13). Atypical, or second-generation, 
antipsychotics were originally greeted with much fanfare because they caused fewer 
extrapyramidal side-effects than first-generation antipsychotics. Also, they were hailed as 
more effective at relieving the negative symptoms of schizophrenia. Clozapine, in 
particular, was considered more clinically effective than any of the first-generation 
antipsychotics, despite its dangerous side-effect profile. As the use of atypical 
antipsychotics grew rapidly, investigators began to notice patterns of side-effects related 
to metabolism. Studies suggested an association between the atypical anti-psyschotic 
medications and weight gain, metabolic syndrome, and even diabetes. All of this 
literature will be discussed extensively in subsequent sections of this thesis. 
Recently, as investigators and physicians have become more aware of the 
metabolic side effects of antipsychotics, and as concern has grown about the negative 
health consequences of overweight and obesity, academics have begun to examine the 
health services question of how doctors and other healthcare providers monitor and 
manage the metabolic status of patients with psychotic disorders. In light of this context, 
it has become questionable whether the common de facto divide between psychiatry and 
the rest of medicine is truly in the best interest of patients. At present, it is understood in 




conduct physical exams or laboratory tests, and that they do not communicate with any 
regularity with internists or surgeons.  
 
Epidemiology and Health Effects of Overweight and Obesity 
 
Based on the 1999-2000 National Health and Nutrition Examination Survey 
(NHANES), over 60% of the United States population is overweight and over 25% are 
obese (14). These conditions are associated with an array of co-morbidities, particular 
cardiovascular disease, hypertension and diabetes (14). Obesity-associated direct costs 
among US adults may exceed 5% of all US healthcare expenditures (15). In the veteran 
population the figures are worse than in the general population: over two in three are 
overweight or obese, and more than one in three is classified as obese (14). A study by 
Mokdad et al. found that weight-related factors such as poor diet and physical inactivity 
followed tobacco as the leading actual causes of death in the United States in the year 
2000, and that they may soon become the greatest actual causes of death (16). The 
Institute of Medicine found that weight loss as low as 5% of total body weight was 
associated a meaningful reduction of morbidity and mortality (17, 18). One would then 
suspect that a similar gain in weight might be associated with the converse (17).  
Guidelines for categorizing weight were set forth by a study performed by the National 
Institutes of Health (NIH) in 1998 (19, 20). It was found that health risks increase as 
patients moved from normal weight through the higher weight categories (17, 21).  
Although considerable evidence has pointed to the adverse health effects of 




relative to a normoweight population, overweight was not associated with cause-specific 
death from cancer or cardiovascular disease (22). Additionally, overweight was actually 
associated with a decrease in non-cancer, non-cardiovascular deaths (22). Obesity was 
associated with increased cause-specific mortality from cardiovascular disease and 
certain obesity-related cancers but it was not associated with mortality from non-cancer, 
non-cardiovascular causes (22). When combined, overweight and obesity were associated 
with increased cause-specific deaths from diabetes and kidney disease (22). This study 
raises the question of what the real implications for overweight are relative to 
normoweight, given that prior to this study one might have assumed that overweight was 
a broadly negative condition. The results even suggest that for certain categories of 
disease overweight may be protective. Flegal’s study does appear, however, to lend 
further support to the claim that obesity leads to adverse health outcomes, particularly 
adverse cardiovascular outcomes. There also appears to be a concerning association 
between overweight and obesity, as a combined category, and diabetes and kidney 
disease. Even though overweight appears to be more benign than obesity, one must be 
concerned that the development of overweight in any given patient may ultimately lead to 
obesity.  
Unfortunately, reversing overweight and obesity is difficult, though surgical, 
behavioral and pharmacological approaches to treatment do exist. Due to the risks posed 
by obesity, in particular, and the difficult of treatment, factors that contribute to the 
development of the condition must be mitigated by physicians whenever possible, 





Antipsychotics and Weight 
 
Due to the co-morbidities associated with overweight and obesity, it is concerning 
that there is strong evidence showing that certain antipsychotic medications cause weight 
gain – evidence that we will return to in detail at a later point. The high prevalence of 
antipsychotic treatment in populations of patients with psychotic disorders makes this 
group of patients particularly at risk for developing overweight and obesity. The 
psychotic population is also at risk simply because it is part of the general US population, 
where overweight and obesity are increasing at alarming rates (14). In addition, patients 
with psychotic disorders often have impairments in self-care that place them at risk for 
unhealthy lifestyles and hence weight gain (7, 8). Indeed, patients with serious mental 
illness have been shown to be at increased risk of developing obesity (6, 23-25), and 
obesity has been associated with excess deaths from cardiovascular disease (22). Also, 
schizophrenia is associated with significantly elevated rates of cardiovascular disease 
relative to the general population (26, 27), and this risk could be magnified by co-morbid 
metabolic dysfunction.  
Treatment-associated weight gain concerning not only because of it may increase 
medical morbidity and mortality, but also because it may be a factor in reducing 
psychiatric medication compliance (17, 28-30), although this association has been 
disputed by some studies (31). Weight gain may have a negative impact on the self-image 
and social status of psychotic patients (30). Indeed, weight gain in patients with 




First-generation antipsychotics have been linked to weight gain, although in 
general the literature shows less concern about these drugs relative to the second-
generation antipsychotics. A 1999 meta-analysis by Allison et al. used a random effects 
model to understand the impact of various antipsychotics on weight (17). The 
investigators found that haloperidol, chlorpromazine and thioridazine/mezoridazine were 
all associated with statistically significant weight gain (17). Fluphenazine, molindone and 
placebo were not associated with weight gain, although non-pharmacologic control was 
associated with a weight gain similar to haloperidol (17). The mean estimated statistically 
significant weight gain for first-generation antipsychotics at 10 weeks ranged from 
approximately 1.08 kg for haloperidol to 3.19 kg for thioridazine/mesoridazine (17). 
These results are of course limited by the quality of studies as well as issues such as 
dosing. Interestingly, the weight effect of the first-generation antipsychotics does not 
appear related to chemical structure or potency (2). Some studies have suggested that 
molindone and diphenylbutylpiperidine pimozide may actually induce weight loss of 
several kilograms (17, 32-34). Interestingly, early studies suggested that successful 
treatment with chlorpromazine was associated with weight gain, whereas weight loss was 
associated with worsening symptoms (35). This finding lines up with the early 
observations by Kraeplin about weight-associated symptom improvement and 
deterioration in schizophrenics (1).  
Second-generation antipsychotics have been closely associated with weight gain. 
Clozapine is one of the best studied atypicals, and there is a well documented association 
between its use and weight gain. Allison et al.’s meta-analysis from 1999 showed a 




weeks (17). Published in 2000, Henderson et al.’s five-year prospective naturalistic study 
of 82 patients taking clozapine found a mean weight gain of 11.6 kg over four years, and 
weight gain did not level off until month 46 (36). Olanzapine has been very clearly linked 
to weight gain as well (17). Risperidone appears to cause less weight gain than 
olanzapine, but the gains are still significant (17). Although quetiapine is a newer drug, 
there is some evidence that it also causes significant weight gain (17, 37). Ziprasidone 
appears to be the one atypical antipsychotic with limited impact on weight (17).  
Allison’s meta-analysis showed no significant association between ziprasidone and 
weight gain (17). This offers clinicians a pharmacologic alternative to be considered if 
their patients gain significant weight on a non-ziprasidone atypical. It should be reiterated 
that according to the same meta-analysis, placebo was associated with weight loss. 
Although this relationship did not reach statistical significance, it does suggest that the 
weight gain associated with atypical antipsychotics is in fact drug-related.  
 
Antipsychotics and Diabetes 
 
Diabetes is a disease characterized by abnormally elevated blood glucose levels. 
The disease is an emerging epidemic in the United States (38). From 2000-2007 the 
incidence of diabetes in the United States increased by 54% (39). According to the Center 
for Disease Control, in 2004 15.2 million Americans had diabetes (www.cdc.gov). 
Particularly worrisome is the growing prevalence and incidence of type 2 diabetes, a 
disease of insulin-resistance, which is often associated with obesity and is contributing to 




of type 2 diabetes can be attributed to excess weight (40). Diabetes affects almost every 
organ system and is associated with numerous serious health risks, including coronary 
artery disease, stroke, peripheral neuropathy, peripheral vascular disease, retinopathy, 
kidney disease, and gastroparesis. Furthermore, diabetics are at further risk of 
complications when in a hospital setting or after surgery (41-43). 
Investigators have noted an association between schizophrenia and diabetes. This 
association was shown to exist before the widespread use of atypical antipsychotics (44, 
45). Nevertheless, in recent years antipsychotics – particularly atypical antipsychotics – 
have been blamed for the rising incidence of diabetes in psychotic patients (46, 47). In a 
recent study by Srihari et al. that examined the prevalence and management of type 2 
diabetes in patients receiving antipsychotic medications, diabetes was two-and-a-half 
times as prevalent in the study population than in the general population (48). The 
authors found that 71% of the 494 patients were taking one or more atypical 
antipsychotics (48). In a naturalistic study of clozapine-naïve patients, it was found that 
over a five-year period of treatment with clozapine, 36.6% of patients developed diabetes 
(36). Interestingly, no significant risk of diabetes was attributed to weight gain, use of 
valproate or clozapine dosing (36). In a large epidemiologic study of 56,849 
schizophrenic patients taking antipsychotics over the span of 1-2 years, Leslie and 
Roesnheck suggested that the attributable risks of diabetes associated with atypical 
antipsychotics was small – ranging from 0.05% for risperidone to 2.03% for clozapine 
(49). Interestingly, the attributable risk for quetiapine and risperidone was not 
significantly different from that for conventional antipsychotics (49). Clozapine and 




patients on antipsychotics it was found that patients taking atypical antipsychotics were 
9% more likely to have diabetes than those who received typical antipsychotics (50). The 
association of atypical antipsychotics and increased prevalence of diabetes was even 
stronger in patients younger than 40 (50).  
A paper by Dixon et al. suggested that patients who had schizophrenia and 
diabetes had better outcomes, as measured by HbA1c, than patients with no severe 
mental illness (51). This suggests although psychotic disorders and the drugs used to treat 
them predispose patients to developing diabetes, such patients are not necessarily unable 
to manage their diabetes. If that is the case beyond this study sample, it raises the 
importance of monitoring for the development of diabetes and then intervening – such 
interventions may be as effective or more effective in schizophrenic patients as in non-
schizophrenic patients. Notably, patients taking olanzapine had higher HbA1c levels than 
patients taking other antipsychotics (51). 
Gianfrancesco et al.  examined the odds of developing type 2 diabetes in diabetes-
naïve patients who were treated with various antipsychotics using data from 2.5 million 
patients cared for by managed care and insurance companies(52). The study period was 
12 months, and patients reporting diabetes up to 8 months prior to the study were 
excluded (52).  Olanzapine, clozapine and certain first generation antipsychotics 
increased the risk of developing diabetes significantly, whereas risperidone did not 
increase risk relative to untreated patients (52).  The finding about risperidone aligns with 
Sernyak’s study (50). In support of Gianfrancesco et al.’s findings, in 2004 Citrome et al. 
found that exposure to multiple second-generation antipsychotics or clozapine or 




Regarding treatment, Klein et al. published an interesting article suggesting that 
metformin is an effective intervention for weight gain, decreased insulin sensitivity, and 
abnormal glucose metabolism related to atypical antipsychotics (54). The limitation of 
this study is that it was conducted in children and adolescents; nevertheless, it may be 
translatable to adult patients and should be studied in that population. In fact, a recent 
study from China, conducted by Wu et al., investigated the value of interventions in 128 
schizophrenic patients using atypical antipsychotics. They found that after a 12-week 
period, patients who received dietary education and partially supervised exercise, 
metformin, or both, had significant weight loss and reduced insulin resistance relative to 
drug placebo (55).  
 
Antipsychotics and Blood Glucose Levels 
 
A growing body of literature has suggested that antipsychotic use may lead to 
changes in blood glucose levels (without necessarily leading to diabetic levels) (56-60). 
Lindenmayer et al. published a prospective randomized double blind trial in 2003 with 
157 patients with schizoaffective or schizophrenic disorder to look at the association 
between antipsychotics and blood glucose level (61). The study was conducted over 14 
weeks (61).  Baseline blood glucose levels were taken before the patients were started on 
therapy, and included a 6-week fixed dose period an 8-week variable dose period (61). 
They found that clozapine, olanzapine, and haloperidol were associated with elevated 
levels of fasting plasma glucose levels (61). Risperidone was not associated with 




not lead to levels associated with the diagnosis of diabetes, although approximately 14% 
of patients did develop diabetic-levels of blood glucose during the course of the study 
(61). However, given Wilson et al.’s finding (below) that glucose intolerance may more 
labile in patients receiving atypical antipsychotics, one wonders whether the point fasting 
blood glucose levels used in this study could be misleading (62).  
A particularly concerning result was noted in a 2002 study by Wilson et al., which 
examined data from 126 patients treated with atypical antipsychotics. The investigators 
found 11 cases of new-onset, acute, and severe glucose intolerance after treatment with 
clozapine, olanzapine or quetiapine (62). Most worrisome, of these 11 patients, 5 
developed diabetic ketoacidosis (62).  Interestingly, glucose metabolism was labile in all 
of the cases, and 2 of the patients had resolution of glucose intolerance despite continued 
treatment with antipsychotics. The authors pointed out that labile glucose intolerance is 
typically suggestive of type 1 diabetogenesis (62). They also made the interesting point 
that many of the symptoms of diabetes overlap with those of antipsychotic medications, 
such as dry mouth, blurry vision, hyperphagia and polyuria, thereby blunting the typical 
triggers for patient alarm (62). Therefore, physicians should always consider diabetes in 
their differential diagnosis of these common side effects of antipsychotics.   
In 2002 Newcomer et al. studied blood glucose levels in 48 schizophrenic patients 
on various antipsychotics relative to 31 healthy controls matched for adiposity and age (2, 
58). First generation antipsychotics were associated with very small increases in blood 
glucose levels after glucose challenge, while the second generation antipsychotics 





Antipsychotics and Metabolic Syndrome 
 
Syndrome X, later renamed metabolic syndrome, was first described in 1988 by 
Gerald Reaven to describe a cluster of risk factors that included hypertension, glucose 
intolerance, high triglycerides, and low high-density lipoprotein (HDL) cholesterol (63). 
Metabolic syndrome has been defined in numerous ways by various organizations over 
the years, but one of the more commonly accepted definitions was published by the 
International Diabetes Federation (IDF) in April of 2005 (64). The IDF defined metabolic 
syndrome by focusing on central obesity. Their definition required a person to have 
central adiposity defined on the basis of waist circumference, and two or more of the 
following four factors: elevated concentration of triglycerides, reduced contentration of 
HDL cholesterol, elevated blood pressure and dysglycemia (64). According to this 
definition, and using US data on adults from the National Health and Nutrition 
Examination Survey data from 1999-2002, Ford calculated that nearly 40% of the US 
population has metabolic syndrome (64). Using the National Cholesterol Education 
Program (NCEP) definition, he calculated the prevalence to be 35% (64).  
The metabolic syndrome has been associated with elevated cardiovascular 
mortality and morbidity, elevated all-cause mortality, and risk of diabetes (63, 65). Using 
the NCEP definition of metabolic syndrome, the relative risk is 1.27 for all-cause 
mortality, 1.65 for cardiovascular disease, and 2.99 for diabetes (65). The population-
attributable fraction for the metabolic syndrome was 6-7% for all-cause mortality, 12-




Lamberti et al. published a cross-sectional study on the prevalence of metabolic 
syndrome in 93 schizophrenic outpatients receiving clozapine relative to 2,701 
comparison subjects (66). The prevalence of metabolic syndrome was significantly 
higher in patients receiving clozapine (53.8%) than among the comparison group (20.7%) 
(66). Within the clozapine population, associations were found with age, BMI, and 
duration of treatment with clozapine(66). The potentially high rate of metabolic 
syndrome in psychotic patients is concerning given that schizophrenia is already 
associated with increased cardiovascular mortality (26, 27). 
 
Putative Mechanisms for Antipsychotic-Induced Metabolic Abnormalities and 
Molecular Assessment of Metabolic Risk in Patients with Psychotic Disorders  
 
Researchers have offered various explanations for the cause of weight gain and 
metabolic disturbance in psychotic patients. None of the evidence is very strong, so most 
hypotheses remain rather speculative. Hypotheses have included ideas related to changes 
in basal metabolic rate, altered levels of baseline physical activity, alterations in appetite 
and satiety, insulin resistance and impaired cellular glucose metabolism.  
Mouse models of visceral obesity and certain human studies have suggested an 
association between visceral fat and metabolic syndrome, leading some researchers to 
believe that the accumulation of visceral fat during antipsychotic use may underlie certain 
metabolic consequences of antipsychotic use (67). Mice overexpressing 11-beta 
hydroxysteroid dehydrogenase develop visceral fat deposition and other metabolic 




also correlates with insulin resistance, suggesting a possible pathological relationships 
where antipsychotics may be involved (68). The hormone resistin may also play a role in 
the development of type 2 diabetes (69). Zhang et al. conducted an imaging study in a 
sample of 46 patients with first-break psychosis (antipsychotic-naïve) to determine 
whether abdominal fat deposition increased after 10 weeks of exposure to an 
antipsychotic, primarily risperidone or chlorpromazine (70). It was concluded that, 
relative to healthy controls without exposure to antipsychotics, the subjects exposed to 
antipsychotics had substantitally increased desposition of subcutaneous and intra-
abdominal fat (70). In these same patients, levels of leptin, fasting lipids, and non-fasting 
glucose were found to be elevated (70). Zhang et al.’s findings may reflect one of the 
reasons that waist circumference has been found to be such an effective tool for 
determining who is at risk for metabolic syndrome (71).  
Certain genes have been associated with the development of metabolic syndrome, 
and interaction between these genes and antipsychotics may result in metabolic 
aberrations in patients (2). Genes putatively involved in the pathways that determine the 
effects of antipsychotics on metabolism include those encoding leptin, the leptin receptor, 
the melanocortin 4 receptor, pro-opiomelanocortin, prohormone convertases, B-
adrenergic receptors in adipose tissue, fatty acid binding protein, lipases, mitochondrial 
proteins, and TNF-alpha and glycogen synthase (2).  
A monozygotic twin study by Theisen et al. lends credence to the hypothesis that 
genetics play an important role in the development of metabolic abnormalities in patients 




first-generation antipsychotics and later clozapine, for a total of 38 kg and 40 kg, 
respectively, over a 2.5 year period (72). 
Zhang et al. found a functional polymorphism -2548G/A in the promoter region 
of the leptin gene that was associated with significantly increased weight gain in 
antipsychotic-naïve patients exposed to antipsychotics (73).  
A prospective study by Basile et al. involving 80 patients treated for 
schizophrenia with clozapine found that weight gain at 6 weeks was correlated with 
polymorphisms in 9 genes encoding seratonin, histamine, adrenergic receptors, 
cytochrome p450 or TNF-alpha (74).   
The relationship between weight gain, certain atypical antipsychotics, and 
activation of the TNF-alpha system have suggested that the TNF-alpha system may 
underlie the relationship between antipsychotics and weight gain (2, 75, 76). TNF-alpha 
and soluble TNF receptor levels are increased in obese subjects (2). Clozapine, 
olanzapine, amitrypitiline and mirtazapine clearly activate the TNF-alpha system (2, 77-
79). Drugs that did not cause weight gain, such as haloperidol, paroxetine and 
venlavaxine did not influence the TNF-alpha system (2, 78). TNF-alpha system 
activation does not appear to be the result of weight gain, because it occurs during the 
first week of treatment (2).  This has led some researchers to suggest that TNF system 
activation might be used as a marker to predict weight gain on an individual basis, 
enabling early alterations in drug choice or dosing (2).  
 





The growing evidence of an association between psychotic disorders, 
antipsychotic drugs, and metabolic abnormalities raises the important question of how to 
best monitor for metabolic disorders in a population with psychotic disorders. In fact, 
there are many questions that must be answered with regard to screening in this 
population, including both those that must be answered by any healthcare screening 
program and those that must be answered in this particular context. For one, there is the 
issue of tests. Which tests are superior in terms of sensitivity and specificity? How should 
the tradeoff between sensitivity and specificity be managed, that is, which is more 
valuable for a particular test? What thresholds should be set for positive and negative 
results? How simple should it be to implement the test? What should prompt a clinician 
to order a test, that is, what positive predictive value ought to be required? Then there is 
the question of what interventions should be provided upon obtaining an abnormal result. 
Should interventions be biological, social, psychological, or some combination of the 
above? Should they be conducted by consults or by the physician ordering the test? 
Finally, related closely to the prior question, there is a health systems question, with 
challenges for providers, payors, and patients. Who should monitor metabolic data in the 
population of chronically mentally ill? Should it be PCCs, MHCs, or someone else? What 
responsibility do psychiatrists have to monitor metabolic data in a patient for whom they 
prescribe a drug that has possible metabolic side effects? If touching and examining 
patients interferes with certain forms of psychotherapy, should such psychotherapists 
abstain from prescribing drugs that require the use of a physical exam to monitor side 
effects? These are very real questions that arise in the context of monitoring metabolic 




historical divisions within psychiatry, between psychiatrist-as-physician and psychiatrist-
as-psychotherapist, continue to play out today.  
There is evidence in the medicine literature that physicians do not adequately 
detect and monitor metabolic abnormalities in the general population. A group at Harvard 
studied 55,000 physician visits from 1995 to 1996 and found that only 8.6% of physicians 
reported obesity in their patients, despite a national a prevalence of 22.7%, according to 
the Third National Health and Nutrition Examination Surveys (NHANTES), 1988-1994 
(80). In 2005 Ruser et al. conducted a cross-sectional study of 424 patients cared for by 
medicine residents in the Yale Internal Medicine Residency Programs and produced 
evidence that internal medicine residents markedly under-recognize and under-treat 
overweight and obesity (81). The problem of under-recognition exists not only in the case 
of weight, but also in the case of diabetes and other metabolic disorders. For example, 
according to the 1999-2002 NHANTES, 30.1% of diabetes in the general population was 
undiagnosed (48). 
There is also inadequate identification and management of overweight and obesity 
in the mentally ill population. Evidence suggests that schizophrenia patients are under-
treated for hypertension, dyslipidemia and diabetes (82). Nasrallah et al. used data from 
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) to evaluate rates 
of non-treatment in schizophrenic patients (82). They found that patients were not treated 
at the following rates: 30.2% for diabetes, 62.4% for hypertension, and 88.0% for 
dyslipidemia (82). Yet in a study by Srihari et al. at a Community Mental Health Center, 
which looked at patients on antipsychotic medications, 13.9% of diabetics in the 




surprisingly higher 30.1% of diabetics who were undiagnosed in the general population 
(48). Additionally, a study by Dickerson et al. suggested that patients with schizophrenia 
and affective disorders were more likely to report receiving some general medical 
services in the past year than the general population, including having visited a general 
medical doctor and having a complete physical exam (83).  
A study very relevant to this thesis was published in 2005 by Buckley et al. (84). 
The investigators collected responses from psychiatrists to a ten-question survey about 
clinical practices with regard to metabolic side effects from second-generation 
antipsychotics. There were 1,534 targets and 258 responses. Although 86% of 
respondents reported altering their prescribing behavior due to the side effect profile of 
second-generation antipsychotics, a full 41.7% of respondents stated that they had 
difficulty obtaining or were unable to obtain resources for determining waist 
circumference (84). Also, 23.3% of respondents stated they had difficulty obtaining or 
were unable to obtain resources for determining fasting blood glucose (84).  Given that 
there is strong evidence that waist circumference and fasting blood glucose are two of the 
most effective tests for monitoring metabolic health risks, the data in Buckley et al.’s 
study is concerning (71, 85-87). The authors also examined baseline testing. They 
defined “frequently testing at baseline” as conducting a test more than 60% of the time 
before initiating therapy (84).  The following percentage of psychiatrists said that they 
ordered the following tests “frequently” prior to initiating antipsychotic therapy: 35% 
glucose, 27% lipids, and 6% waist circumference (84).  Less than 25% of psychiatrists 
obtained a blood pressure measurement “frequently” prior to initiating antipsychotic 




after starting a second generation antipsychotic, they did not routinely obtain the 
following tests: waist circumference, glucose, blood pressure, or lipid profile (84).  Less 
than 25% of psychiatrists took a monthly weight (84).  These results suggest that, in the 
context of prescribing second-generation antipsychotics, routine monitoring of metabolic 
metrics has not become a norm in psychiatry – in contrast to all recommendations from 
expert panels to date (85-87). It appears, according to Buckley et al., that “although 
clinicians are aware of the emergent side effect profile of second-generation 
antipsychotics … the impact of recent guidelines upon actual practice is, at best, modest. 
This is an evolving standard of care” (84).  
A paper by Motsinger et al. reviewed pharmacy data from a community health 
center over a 6-month period for patients prescribed atypical antipsychotics (88). They 
found that 13% of patients prescribed atypical antipsychotics had fasting blood sugar 
levels and 30% had lipid panels measured during the six month study period (88).  
Psychiatrists ordered tests at the lowest rates, and physicians trained in primary care plus 
psychiatry ordered such tests at the highest rates (88). 
In terms of cost effective screening for metabolic syndrome, Straker et al. 
produced evidence suggesting that abdominal obesity was most sensitive, at 92%, while 
fasting glucose was most specific, at 95.2%, for identifying the presence of metabolic 
syndrome (85). Combining abdominal obesity and elevated fasting blood glucose had 
100% sensitivity (85). They concluded that measuring abdominal obesity via weight 
circumference and fasting blood glucose was a simple and cost-effective means of 




A group in Canada, Ardern et al., determined that waist circumference (WC) was 
an effective tool for detecting metabolic syndrome in women with elevated BMI, but not 
in men (89). Janssen et al. found that WC cutoffs helped to identify increased health risk 
within all weight categories, including normal (71). The health risks that they reviewed 
included hypertension, diabetes, dyslipidemia and the metabolic syndrome (71). 
Marder et al. published recommendations for physical health monitoring of 
patients with schizophrenia (86). The paper was a direct result of a conference at Mount 
Sinai School of Medicine in New York that had focused on the topic (86, 87). The 
authors suggested (1) clinics be capable of weighing patients; (2) patients should be 
encouraged to track their own weight; (3) BMI monitoring should be supplemented by 
waist circumference recording; (4) patients should be weighed at every visit for the first 6 
months of treatment or after a medication change (86). The authors also believed that a 
gain of 1 unit BMI, or a waist circumference of 35 inches for women and of 40 inches for 
men, indicates the need for an intervention (86). In addition, the authors determined that a 
BMI over 25 should be cause for considering the relative risks of weight gain posed by 
different antipsychotics (86). They emphasized that clinicians should make an effort to 
recognize weight gain early to prevent weight gain and obesity, as reversal of these 
phenomena is extremely difficult (86).  
With regard to diabetes monitoring, the Marder/Mount Sinai group had further 
recommendations. They suggested obtaining an initial fasting plasma glucose level 
before starting any new antipsychotic, with HbA1c as a secondary option (86). They 
recommended further testing of fasting glucose or HbA1c every 4 months if patients 




circumference) or if the patient gains weight during antipsychotic treatment (86). 
Providers should inform and ask patients about diabetes symptoms such as polydipsia, 
polyuria and weight change (86). 
The Marder/Mount Sinai group also had recommendations regarding lipid 
monitoring (86).  They suggested that all patients with schizophrenia should have a lipid 
panel performed, including total cholesterol, LDL, HDL, and triglycerides (86). If LDL is 
normal, it should be re-tested every 2 years, but if it is above 130 mg/dl, it should be 
tested every 6 months (86). Mental health practitioners should identify patients who 
fulfill the criteria for metabolic syndrome and should consider all patients with 
schizophrenia at risk for coronary artery disease (86). 
An article in the British literature recommends an even more aggressive initial 
evaluation and early monitoring of metabolic metrics in schizophrenic patients. For 
example, they suggest obtaining monthly weights (90). 
A 2006 review by Cohn et al. (91) points out that there is a dearth of literature 
about the cost-effectiveness of metabolic monitoring of patients taking antipsychotics 
(91). Also, Cohn et al. suggested that although psychiatrists do not have the obligation of 
becoming experts at the diagnosis and treatment of disorders such as obesity, 
hypertension, heart disease and diabetes, they do carry responsibility for delegating 
responsibility to qualified experts when appropriate (91). 
Using a randomized controlled trial method, Druss et al. looked at organizational 
structures and the effectiveness of novel structures relative to standards (92). They 
contrasted outcomes in an integrated care system at the Veterans Affairs medical system, 




integrating care, they found psychiatric patients were more likely to visit a primary care 
physician and had a greater mean number of visits to a primary care clinician (92). They 
also determined that patients had significantly improved general health as measured by 
the 36-item Short-Form Health Survey (92). Although general health improved, there was 
no improvement in mental health (92). Importantly for healthcare administrators, the cost 
of the two systems was equivalent (92). This system is in fact that one at which the data 
for this thesis was collected. 
 
STATEMENT OF PURPOSE 
 
We are at an interesting point in the history of psychiatry in which crucial 
questions are emerging about the role and responsibility of psychiatrists and other mental 
health clinicians (MHCs) in monitoring, reporting, and managing the medical illness of 
their patients, as well as the medical side-effects of prescribed psychiatric medications.  
The emergence of powerful biological treatments for psychiatric disorders, along with an 
increased awareness by clinicians of the medical and biological dimensions of psychiatric 
illness, has led to a gradual closing of the historical schism that existed between 
psychiatry and the rest of medicine since the beginning of the psychoanalytic era. This 
thesis aims to contribute productively to the discussion about the role MHCs currently 
play in monitoring a potentially life threatening medical side-effect of second generation 
antipsychotic medications. We ask this key question:  How do MHCs and primary care 




with psychotic disorders? In answering that question, we will attempt to answer a second 
key question: should the status quo change and if so, how?  
The scientific means for answering our first key question is to put forth a 
hypothesis and then test it with empirical data. Our null hypothesis is that there is no 
difference in the rates of monitoring, identifying and intervening for metabolic 
abnormalities by MHCs and PCCs at the Veteran’s Affairs facilities in West Haven, 
Connecticut. Should we reject the null hypothesis, we secondarily hypothesize that 
MHCs monitor, report and intervene for metabolic abnormalities in their patients at rates 
that are significantly lower than those of PCCs, and that such rates are too low. The 
results of our hypothesis testing will enable us to put forth an answer to our second key 
question, which was whether the status quo should change and if so, how. 
 
MATERIALS AND METHODS 
 
Study Overview  
 
We performed a cross-sectional medical record review of overweight and obese 
patients with psychotic disorders at the Mental Hygiene Clinic at the West Haven 
Campus of the Veterans Affairs Connecticut Healthcare System (VACHS). The study 
was approved by the VACHS Human Investigations Committee. As data was extracted 







We searched the VACHS electronic medical record database for patients who met 
the following inclusion criteria: (1) primary diagnosis of schizophrenia or schizoaffective 
disorder (from DSM-IV, International Classification of Disease codes 295.10, 295.30, 
295.60, 295.70, and 295.80); (2) at least one routine mental health visit at the West 
Haven VA facility (VA stop codes 502, 552 and 576) between July 1, 2005 and June 30, 
2006; and (3) overweight or obese, as determined by a body mass index (BMI) > 25. We 
excluded all deaths. After identifying subjects who met all of our selection criteria, we 
had a remaining cohort of 123 subjects.  
 
Data Extraction Methods 
 
We parsed the electronic medical records of subjects in the cohort and extracted 
relevant data from July 1, 2005 through June 30, 2006. Data was first recorded on 
standardized paper sheets (see Appendix) and then entered into Microsoft Excel 
spreadsheets. For each subject, we examined general patient background data, primary 
care clinician (PCC) visit notes, and mental health clinician (MHC) visit notes. We only 
examined data from routine outpatient visits, ignoring emergency room visits and 
hospitalizations. 
 Two psychiatrists, one primary care physician, and one medical student extracted 
data from the medical records. In order to develop a standardized process for extracting 
and recording data, and so as to decrease inter-rater variability, all raters reviewed the 




extraction form and discussions about the process improved the subsequent 
standardization of data collection.  
 We extracted data regarding age, sex, race/ethnicity, weight, BMI, alcohol and 
tobacco use, co-morbidities, antipsychotic treatment, number of PCC visits, and number 
of MHC visits. Co-morbidities extracted from the past medical history section of notes 
included diabetes type 1, diabetes type 2, hypertension, hypercholesterolemia, 
dyslipidemia, osteoarthritis or degenerative joint disease, obstructive sleep apnea, 
hyperthyroidism, metabolic syndrome, and coronary artery disease. We examined 
clinician notes for documentation of the following information: waist size, weight, height, 
and BMI. We recorded identifications of weight in the problem list, history of present 
illness, or assessment and plan of clinician notes. We recorded whether clinicians 
identified a linkage between weight and antipsychotics and whether they recommended 
weight loss as a therapy for a diagnosis other than obesity. We also recorded whether 
clinicians documented ordering any of the following laboratory tests in their notes: blood 
glucose, thyroid stimulating hormone (TSH), urinalysis, lipid panel, or hemoglobin A1C.  
 Finally, we recorded instances when interventions related to weight management 
were documented in clinician notes. We determined whether a weight-related referral was 
made for a nutrition/dietician, physical therapist, behavioral modification clinic, social 
worker, endocrinologist, surgeon or other consultant. We recorded whether the clinician 
made dietary or exercise recommendations. We also determined whether 
pharmacotherapy for weight loss was considered or ordered, and whether a change in 







After collecting all the data, we analyzed it in Microsoft Excel. For continuous 
variables such as weight, we calculated descriptive statistics such as mean, median, 
mode, range, minimum, maximum, and standard deviation. For discrete variables 
characterized by either a positive or negative value, we calculated sample proportions. 
For any given variable there were two samples, one from primary care and one from 
mental health, so it was necessary to compare the sample proportions from these two 
groups in order to determine whether the clinician groups acted differently. Towards that 
end, we calculated 95% confidence intervals for the difference in sample proportions (see 
equation below). (All confidence intervals reported in this thesis can be assumed to be 
95% confidence intervals for the difference in two proportions.) If the confidence interval 
did not cross zero, the difference was deemed statistically significant. We also calculated 
a p-value for the difference in sample proportions by setting the lower bound of the 
confidence interval equal to zero, determining the subsequent z-score, and thereby 



















(Note: All tables are displayed in the text body but have also been consolidated in 
the Appendix.)  
As displayed in Table 1, we found that in our population of 123 subjects, a 
majority of subjects were white (56%). African-Americans (21%) and Not Documented 
(20%) comprised significant minorities. Only 2% of subjects were Hispanic. As shown in 
Table 2, our subjects were predominantly male (93%), and the remaining only 7% were 
documented as female.  
Table 1: Subject Race/Ethnicity (N=123) 
 Percent  
Not Documented 20%  
White 56%  
Hispanic 2%  
African-American 21%  
Other 1%  
 











 Statistics regarding the age, weight, BMI and number of routine office visits by 
subjects are presented in Table 3. The mean age of subjects was 54 years (SD=8 years). 
Subjects were overweight or obese: the mean weight was 218 pounds (SD=25 pounds) 
and the mean BMI was 32.4 (SD=5.4). Subjects visited mental health providers more 
often than primary care providers. The mean number of PCC office visits was 3.4 visits 
(SD=4.0 visits); the mode was lower at 2.0 visits. The mean number of MHC visits was 
15.6 (SD= 11.1 visits); the mode was lower at 12 visits.  
Table 3: Age, Weight, BMI, and Number of Routine Office Visits (N=123) 
     











 Mean 54 218 32.4 3.4 15.6  
 Median 54 215 31.3 2.0 12.0  
 Mode 54 233 31.7 2.0 12.0  
 Minimum 31 137 25.0 1.0 1.0  
 Maximum 85 312 50.5 41.0 59.0  
 Range 54 175 25.5 40.0 58.0  
 
Standard 
Deviation 8 35 5.4 4.0 11.1  
 
Table 4 displays data on alcohol and tobacco use, as well as the co-morbidities 
that were extracted from the past medical history data found in clinician notes. In our 
sample, 51% of subjects were tobacco smokers. The most prevalent co-morbidities were 




and dyslipidemia (40%). 10% of subjects carried diagnoses of diabetes, hypertension and 
dyslipidemia, thus meeting the criteria for metabolic syndrome – and yet there was not a 
single diagnosis of metabolic syndrome in the entire sample. The prevalence of coronary 
artery disease was 9%.  
Table 4: Subject Co-morbidities (N=123) 
 Percent
Diabetes Type I 1%






Obstructive Sleep Apnea 10%
Hypothyroidism 5%
Metabolic Syndrome 0%
Coronary Artery Disease 9%
Any Smoking (current) 51%
Any Alcohol Use (current) 21%
High Alcohol Use (current)      
(women >7 drinks per week; 
men >14 drinks per week) 9%
  
Table 5 shows data about the rates of antipsychotic treatment in the sample 
population, as determined from clinician notes. We found that 37% of subjects were 




antipsychotic, 97% were prescribed at least one antipsychotic of any type, and 25% were 
prescribed both a first-generation and a second-generation antipsychotic. The following 
percentage of subjects were prescribed particular second-generation antipsychotics: 10% 
aripiprazole (Abilify); 11% clozapine (Clozaril); 22% olanzapine (Zyprexa); 24% 
quetiapine (Seroquel); 29% risperidone (Risperdal); and 8% ziprasidone (Geodon).  
Table 5: Rates of Antipsychotic Therapy (N=123) 
 Percent  
Prescribed First Generation Antipsychotic 37%  
Prescribed Second Generation Antipsychotic 85%  
Prescribed at Least One Antipsychotic of 
Any Type 97%  
Prescribed Both a First and Second 
Generation Antipsychotic 25%  
Aripiprazole (Abilify) 10%  
Clozapine (Clozaril)  11%  
Olanzapine (Zyprexa) 22%  
Quetiapine (Seroquel) 24%  
Risperidone (Risperdal) 29%  
Ziprasidone (Geodon) 8%  
  
Table 6 shows the rates at which PCCs and MHCs documented weight-related 
biometrics. In the sample population, not a single subject had their waist-size documented 
by a PCC or MHC. Waist-size is a fundamental biometric used for assessing risks 
associated with metabolic syndrome. Far more subjects had their weight documented by 




documentation of BMI (48% vs. 0%; CI 0.39-0.57; p<0.001). It is notable that MHCs 
also failed to document BMI in any subjects.  
Table 6: Documentation of Biometrics in Visit Notes (N=123) 










Waist size  0% 0% - - -
Weight  85% 11% 0.66 0.82 <0.001
Height 59% 2% 0.48 0.66 <0.001
BMI 48% 0% 0.39 0.57 <0.001
 
 Table 7 displays the rates at which PCCs and MHCs identified weight as an issue 
in their notes. PCCs identified the issue of weight more often than MHCs (45% vs. 28%; 
CI 0.04-0.28; p<0.005). PCCs were also far more likely than MHCs to mention weight 
loss as a therapy for a diagnosis other than obesity (28% vs. 4%; CI 0.15-0.32; p<0.001). 
PCCs and MHCs rarely identified the link between antipsychotics and weight issues in 





Table 7: Identification of Weight Issues Documented in Visit Notes (N=123)  










Identified weight as an issue in 
problem list 28% 13% 0.06 0.25 <0.005
Identified  weight as an issue in 
history 26% 15% 0.01 0.21 <0.015
Identified weight as an issue in 
assessment and plan 39% 17% 0.11 0.33 <0.001
Identified  weight as an issue in 
at least one of the following: 
problem list; history; assessment 
and plan 45% 28% 0.04 0.28 <0.005
Identified link between weight 
and antipsychotics 10% 12% -0.10 0.05 0.730
Identified weight loss as a 
therapy for a diagnosis other 
than obesity 28% 4% 0.15 0.32 <0.001
 
 As shown in Table 8, PCCs ordered laboratory tests that can identify metabolic 
abnormalities far more often than MHCs did. For every test, including blood glucose, 
thyroid stimulating hormone, urinalysis, lipid panel, and hemoglobin A1C, there was a 




ordered tests by PCCs versus by MHCs. For example, PCCs ordered a blood glucose for 
50% of subjects and MHCs only did so for 4% of subjects (CI 0.36-0.55; p<0.001). 
Table 8: Tests Ordered in Visit Notes (N=123) 










Blood glucose 50% 4% 0.36 0.55 <0.001
TSH  15% 4% 0.04 0.19 <0.005
Urinalysis  14% 0% 0.08 0.20 <0.001
Lipid panel  71% 2% 0.61 0.77 <0.001
Hemoglobin A1C  25% 2% 0.16 0.32 <0.001
 
 Table 9 shows the weight-management interventions that were documented by 
PCCs and MHCs. PCCs were more likely than MHCs to make dietary and exercise 
recommendations to subjects (42% vs. 19%; CI 0.12-0.35; p<0.001) and they were also 
more likely to order a weight-management referral (21% vs. 3%; CI 0.10-0.26; p<0.001). 
Although MHCs were more likely than PCCs to order or to consider ordering a change of 
antipsychotic medication or dose due to weight-related issues (6% vs. 3%), the difference 
was not statistically significant. The low rates at which clinicians considered altering 
antipsychotic prescriptions for weight-related reasons is echoed by the low rates at which 





Table 9: Interventions For Weight Loss Documented in Visit Notes (N=123)  










Made dietary recommendations to 
patient 57% 25% 0.20 0.43 <0.001
Made exercise recommendations to 
patient 46% 22% 0.12 0.35 <0.001
Made exercise and dietary 
recommendations to patient 42% 19% 0.12 0.35 <0.001
Ordered at least one referral for weight 
management 21% 3% 0.10 0.26 <0.001
Considered or ordered 
pharmacotherapy for weight loss 1% 0% -0.01 0.02 0.158
Considered or ordered change of 
antipsychotic medication due to weight 2% 4% -0.06 0.03 0.764
Considered or ordered change of 
antipsychotic dose due to weight  2% 5% -0.07 0.02 0.846
Considered or ordered change of 
antipsychotic medication and/or dose 







In order to better understand how mental health clinicians (MHCs) and primary 
care clinicians (PCCs) identify, monitor and intervene for metabolic disorders in patients 
with psychotic disorders, we studied the medical records of 123 overweight or obese 
veterans (BMI ≥ 25) with psychotic disorders at the Veteran Affairs outpatient facilities 
in West Haven, Connecticut during a one year period from July 1, 2005 to June 30, 2006. 
Our subjects were predominantly white and male (56% and 93%, respectively), with an 
average age of 54 years (SD=8 years). The subjects had an average weight of 218 pounds 
(SD=35 pounds) and an average body mass index (BMI) of 32.4 (SD=5.4). We found that 
97% of subjects were taking an antipsychotic of some sort, and 85% were taking a 
second-generation antipsychotic – the category most frequently associated with metabolic 
side effects. The most frequently prescribed second-generation antipsychotics were 
risperidone (29%), quetiapine (24%), and olanzapine (22%), all of which have been 
associated with metabolic side-effects in the medical literature – particularly risperidone 
and olanzapine (see Introduction for details). In general, we found that, despite far more 
average annual visits to MHCs than PCCs (15.6 visits vs. 3.4 visits), PCCs were much 
more likely than MHCs to identify, monitor and treat a variety of weight and metabolic 
parameters in our study population over the course of a year.  
Our results have led us to reject the null hypothesis that there is no difference in 
the rates of monitoring, identifying and intervening for metabolic disorders by MHCs and 
PCCs at the Veteran’s Affairs facilities in West Haven, Connecticut. We also accept our 




abnormalities in their patients at rates that are significantly lower than those of PCCs. We 
will discuss the evidence leading to these conclusions in the subsequent sections of this 
Discussion.   
 
Documentation of Biometrics by Clinicians 
 
MHCs documented weight-related biometrics at extremely low rates, both 
absolutely and relative to PCCs. During the one-year study period, MHCs documented 
weight measurements for only 11% of subjects, whereas PCCs documented weight 
measurements for 85% of subjects (CI 0.66-0.82; p<0.001). Similarly, MHCs 
documented BMI for 0% of subjects, whereas PCCs documented BMI for 48% of 
subjects (CI 0.39-0.57; p<0.001). Our findings are concerning because they suggest that 
PCCs were seven to eight times more attentive to measurements of weight than MHCs, 
despite the fact that 97% of subjects in the study were prescribed antipsychotics by 
MHCs. A possible explanation for the disparity between clinician groups is that MHCs 
might expect PCCs to monitor the weight-related side effects of the antipsychotics that 
MHCs prescribe. Also, MHCs may not have the resources to perform weight monitoring, 
such as scales and support staff.  That being said, even if MHCs do rely upon PCCs to 
perform all metabolic monitoring, such an expectation should be explicit and the results 
from primary care consultations and follow-up should be documented clearly in mental 
health visit notes.  
 





It is concerning that, although our subjects carried significant rates of diagnoses 
that are associated with metabolic syndrome, including 23% type 2 diabetes, 55% 
hypertension, and 38% dyslipidemia ―10% of subjects carried all three diagnoses―, 
there was not a single clinician that identified a subject as having metabolic syndrome. It 
seems highly unlikely that, in the setting of such co-morbidities, there was truly a 0% 
prevalence of metabolic syndrome in the cohort. Moreover, given that the literature 
suggests that the general prevalence of metabolic syndrome in the United States may be 
as high as 40%, clinicians in our study were likely significantly under-diagnosing 
metabolic syndrome (64). We also determined that zero subjects were measured for a 
waist-circumference by a PCC or MHC during the study period. This too is alarming, 
given that the literature has deemed waist circumference to be one of the most valuable 
metrics for diagnosing metabolic syndrome risk and for assessing associated health risks 
(see Introduction for details) (71, 85). Our results indicate that the level of clinician 
awareness about metabolic syndrome, and the rate at which it is diagnosed and followed 
by PCCs and MHCs, may be grossly inadequate. Given the morbidity associated with 
metabolic syndrome, and the baseline cardiovascular risks associated with schizophrenia 
(26, 27), our findings suggests that subjects in our study may face significantly greater 
health risks if the quality of monitoring is not improved. 
 





We examined the rate at which clinicians listed weight as an issue in certain key 
sections of the visit note, including the problem list, the past medical history, and the 
assessment and plan. When we evaluated how often clinicians identified weight as an 
issue in at least one of these sections of the visit note, the difference between groups was 
significant: PCCs identified weight as an issue in 45% of subjects, whereas MHCs 
identified it in only 28% of subjects (CI 0.11-0.33; p<0.005). Thus weight does not 
appear to be a standard issue addressed by clinicians in patients who are overweight or 
obese.  
 We also found that both MHCs and PCCs infrequently identified the link between 
antipsychotics and weight gain in their notes (10% vs. 12%; not a statistically significant 
difference). Given the extensive literature linking antipsychotics to weight gain, which 
we discussed in the Introduction, the fact that all of the subjects in our study were 
overweight or obese, and the fact that almost all subjects were taking an antipsychotic, 
clinicians should have remarked on this linkage more frequently in their notes. The 
failure to identify the link between antipsychotics and weight was echoed by the low rates 
at which PCCs and MHCs ordered or considered ordering adjustments to antipsychotic 
prescriptions due to metabolic side-effects (3% and 6%, respectively; not a statistically 
significant difference). It is surprising that, despite MHCs’ expertise in 
psychopharmacology and their role as the primary prescribers of antipsychotics in our 
study sample, they did not significantly outperform PCCs on criteria of linkage or 
prescription change.  
 Interestingly, PCCs were also much more likely than MHCs to recommend 




This reveals that, at least as understood by their documenting habits, PCCs displayed a 
greater awareness of the health benefits offered by weight loss beyond merely loss of 
weight (e.g. lower triglycerides and lower blood pressure). Given that PCCs are tasked 
with monitoring and treating a much wider range of medical conditions than MHCs (e.g. 
diabetes and heart disease), it makes sense that they would be more attuned to, and 
concerned about, how weight issues interact with non-psychiatric disease processes. At 
the same time, given that the schizophrenic psychiatric population faces increased risks 
for several co-morbid medical diseases and conditions (26, 27, 93), MHCs should be 
attentive to those risks and how they are monitored.  
 
Laboratory Testing and Intervention by Clinicians 
 
On almost every dimension of laboratory testing or intervention that we studied in 
clinician notes, PCCs were more interventionalist than MHCs. According to their notes, 
PCCs ordered all of the following tests at higher rates than MHCs: glucose (ordered for 
50% versus 4% of subjects; CI 0.36-0.55; p<0.001); thyroid stimulating hormone (15% 
versus 4%; CI 0.04-0.19; p<0.005); urinalysis (14% versus 0%; CI 0.08-0.20; p<0.001), 
lipid panel (71% versus 2%; CI 0.61-0.77; p<0.001); and hemoglobin A1c (25% versus 
2%; CI 0.16-0.32; p<0.001). In terms of interventions, PCCs documented ordering at 
least one referral for weight or metabolic-related concerns for 21% of subjects, whereas 
MHCs only did so for 3% of subjects (CI 0.10-0.26; p<0.001). In terms of counseling, 




19% of subjects (CI 0.12-0.35; p<0.001). Additionally, only one PCC – and not a single 
MHC – mentioned pharmacotherapy for weight loss in their note. 
 As mentioned earlier, rates of recommending a change of antipsychotic drug or 
dose were very low among both PCCs and MHCs (3% vs. 6%; not a statistically 
significant difference). This was surprising, given that the literature has documented that 
different antipsychotics carry different metabolic risk profiles, and hence patients who 
experience metabolic side-effects from one antipsychotic may benefit from a change to 
another drug or a lower dose (see Introduction for details). Our data suggests that MHCs 
may be focusing primarily on the management of psychiatric symptoms without devoting 




Since our study focused exclusively on veterans who receive their care within a 
single healthcare system, it is difficult to extrapolate the results to other settings, such as 
private practice psychiatry, prisons, or other state-funded medical centers. Also, one of 
the primary care clinics at the West Haven VA, where we conducted our study, is in the 
same building as a mental health clinic and focuses specifically on patients with severe 
mental illness. This sort of integration and communication between primary care and 
mental health is not standard in the nation. One would suspect that this model actually 
enhances both PCC and MHC awareness about the metabolic side-effects of 
antipsychotics, and thus that more disjoined healthcare delivery systems would perform 




 It is worth noting that the PCCs and MHCs who cared for the subjects in our 
study had varying levels of professional education and expertise. For example, PCCs 
were predominantly attending physicians, resident physicians, and advanced practice 
registered nurses (APRNs), whereas MHCs included a broad mixture of attending 
physicians, resident physicians, APRNs, registered nurses (RNs), psychologists, and 
social workers (although 93% had contact with an attending physician, resident 
physician, or APRN during the study period). It is not clear how this diversity of 
caregivers affected rates of identification, monitoring and treatment in the PCC and MHC 
groups.  
 Our study is also limited by the fact that we primarily gathered clinical data from 
clinician notes, rather than from laboratory transactions or directly observed behavior. 
The focus on documentation could have led to a biased representation of actual clinician 
behaviors. First, if the culture and attitudes that inform MHCs’ documentation habits 
differ significantly from those of PCCs, then the two groups could have systematic 
differences in documentation outputs. For example, it might be the case that PCCs write-
up their blood glucose orders in notes more regularly than MHCs, even though the two 
groups might actually request blood glucose orders at identical rates. Likewise, MHCs 
and PCCs might identify weight as an issue and counsel patients on diet and exercise at 
equal rates, but they might document such findings and actions differently. If these types 
of systematic documentation differences exist between groups, then our study would 
reveal more about communication and the documentation of behaviors than it would 




differences by comparing documentation in notes to laboratory orders or observed 
behaviors. 
 Aside from systematic inter-group documentation biases, there may also be 
general documentation issues affecting our study. It is likely that clinicians only 
document a limited sample of the behaviors that they actually perform, and similarly, that 
they only document a limited sample of the clinical knowledge that they generate. Thus 
documentation rates may appear much lower than one would expect. A good example of 
this might be coronary artery disease: if clinicians did not document the condition, then 
we did not see it in the past medical history, and so the rates of coronary artery disease 
may have appeared low – even if clinicians were aware of and treating the condition.  
 Another documentation issue that may have impacted our study results is that 
PCCs may have issued the orders that we examined for reasons unrelated to 
antipsychotics or metabolic issues (e.g. ordering a urinalysis to assess urinary tract 
infection symptoms). This activity may have muddled our comparisons between PCCs 
and MHCs on the basis of tests ordered, because MHCs are responsible for identifying 
and treating a more limited panel of non-psychiatric diseases than PCCs.  
 We used three physicians and one medical student to analyze the medical records 
and this raises the possibility that there was inter-rater variability. In addition, there may 
have been intra-rater variability, considering the large amount of note material that we 
were evaluating. For example, there is a certain degree of subjectivity in determining 
whether a clinician has definitively “identified a link between weight and antipsychotics 
as an issue” in his or her note, and a rater’s analysis may vary for a given rater or between 




the raters gathered on a regular basis to compare approaches and to discuss ambiguous 
cases. Furthermore, during the first four weeks of analysis the group met weekly to 
discuss a set of comparison cases thereby helping to standardize data collection methods.  
 Our study looked at collective rates of identification, monitoring and treatment 
across a one-year period, yet this may have masked the disparities that exist on a per-note 
basis. For example, “identified weight as an issue” was marked a positive “yes” if it 
occurred at least once in a clinician note during the one-year period. So there could have 
been many positives among either many or few notes during the year, or a single positive 
among either many or few notes. In all of these cases the outcome would be the same: a 
positive “yes.” This phenomenon of ambiguity could also occur in the case of negatives. 
If the data had been examined on a per-note basis, we may have found either an 
amplification or diminution of differences between PCCs and MHCs. Our suspicion is 
that, since the average number of MHC visits in our study was much higher than the 
number of PCC visits (15.6 visits vs. 3.4 visits), the differences would in fact be 
amplified, lending further evidence to support our finding that, relative to MHCs, PCCs 
more aggressively identify, monitor and treat metabolic dysfunction in patients with 
psychotic disorders. 
 
General Implications of Study Results 
 
MHCs often prescribe antipsychotics that cause metabolic side-effects to patients 
with psychotic disorders, and yet our study has shown that they infrequently monitor such 




that were reported in Buckley et al.’s survey of physicians, from which the researchers 
concluded, “Although clinicians are aware of the emergent side-effect profile of second-
generation antipsychotics … the impact of recent guidelines upon actual practice is, at 
best, modest. This is an evolving standard of care” (84). Our results also show that 
patients suffering from psychosis interact more frequently with MHCs than PCCs, and in 
the general community many psychotic patients probably do not regularly see PCCs. This 
creates a situation that allows patients who develop side-effects to fall systematically 
through the cracks of the “monitoring system” (if such a system could accurately be said 
to exist). It seems that MHCs should be charged with the primary responsibility to 
monitor the side-effects of the drugs they prescribe. Just as MHCs are professionally 
responsible for monitoring for agranulocytopenia in patients who take clozapine, MHCs 
should also be responsible for monitoring for metabolic side-effects in patients who take 
antipsychotics, particularly second-generation antipsychotics. Indeed, MHCs should be 
identifying and monitoring patients with metabolic disorders for a variety of reasons: (1) 
MHCs prescribe the antipsychotics that cause metabolic side-effects; (2) MHCs see their 
patients more often than PCCs; (3) patients without access to PCCs may still access 
MHCs; (4) MHCs often understand patients’ biopsychosocial context better other 
clinicians; and (5) MHCs often have very strong relationships and interpersonal leverage 
with their patients. Relative to the Mount Sinai Conference guidelines regarding 
monitoring for the metabolic side-effects of antipsychotics, which we discussed in detail 
in the Introduction, the MHC system in our study, and perhaps nationally too, is 
underperforming (86, 87). Rather than describing this situation as an “evolving standard 




as a “dangerous failure in quality control.” Indeed, undetected metabolic side-effects 
from atypical antipsychotics can be life-threatening. This story is yet another example of 
the serious quality control problems that are rampant in American healthcare. Quality 
control systems in American healthcare are abysmal when compared to those of 
industries such as the airline industry or of companies such as Toyota.  
 After MHCs identify patients with develop metabolic side-effects, the subsequent 
step is either to manage the issue themselves or to obtain a consultation from a specialist 
who can do so. Our study suggests that neither active management of side-effects nor the 
consultation of specialists is happening adequately today. 
 There is no value in merely pointing fingers or allocating blame for what is 
without question a system-wide failure of quality control. Instead, efforts must be made 
by leadership at both the local and national level to introduce systemic reforms that will 
ensure that all patients will be appropriately monitored and treated for the metabolic side-
effects of antipsychotics. 
 Briefly, we might gain some insight on today’s quality-control problem by 
speculating about its historical origins. It is not unreasonable to suspect that today’s 
problem began with the historical separation of psychiatry and the rest of medicine. In the 
past, both the lack of biological treatments for psychiatric disorders and the dominance of 
psychoanalytic practice, in which the patient’s body was rarely if ever touched, led the 
daily routines of psychiatry to diverge from the rest of medicine. Metaphorically, the 
stethoscope was put aside and replaced by the couch. But since the advent and 
proliferation of biological treatments, such as antipsychotics, those routines have needed 




though the historical residue indeed persists, leaving us with a psychiatric approach to 
patient care, and a system of mental health, that continues to focus insufficient attention 
on the body relative to the mind.  
 
Options for a Local Response to Study Results 
 
If the implications of our findings are interpreted narrowly, so as to apply only 
locally, then we should examine what our findings mean for the West Haven VA. Clearly 
the metabolic parameters of patients on second-generation antipsychotics are not being 
adequately followed by MHCs at the West Haven VA, and this is systemic quality 
failure. Thus system reform is critical. Six solution frameworks can be used to quickly 
address the quality failure: (1) establish quality goals and objectives; (2) appoint 
leadership; (3) educate; (4) allocate resources; (5) facilitate dialogue; and perhaps most 
importantly, (6) standardize work processes. 
 Within each of these six frameworks, there are some very direct steps that the 
West Haven VA could take to have rapid impact. Quality improvement could be declared 
a goal, supported by explicit and measurable objectives. A leader could be appointed to 
coordinate and monitor the organization’s drive toward quality improvement. This leader 
should be familiar with the tools and concepts of quality management (94-98).   In terms 
of education, sending a letter to all MHCs regarding the findings of this study, along with 
a copy the Mount Sinai guidelines, would be one way to initiate an awareness campaign. 
Our findings and the Mount Sinai guidelines could be presented at a mental health staff 




in the mental health clinics as a reminder to staff about the importance of monitoring for 
metabolic disorders, and information about the weight and diabetes management referral 
resources that are available to clinicians at the VA could be consolidated and 
disseminated to providers. In terms of resource allocation, leadership would need to first 
determine what resources are already in place, followed by the deployment of budgetary 
resources and personnel to address gaps (e.g. lack of scales, measuring tapes, or technical 
staff).  Regarding facilitating a dialogue, gatherings could be organized to bring together 
clinicians from different areas of the West Haven VA provider community in order to 
discuss ways to improve the management of metabolic disorders within the network. 
Finally, in order to standardize processes, management at the West Haven VA could put 
in place a clinical reminder that “pops up” in the electronic medical record of overweight 
or obese patients who take antipsychotics. This would remind MHCs to evaluate the 
weight and other metabolic parameters of such patients. By standardizing the work 
process in this way, variance in clinician behavior would drop and quality of care would 
subsequently improve.  
 Another issue to address is that of process standards for documentation and notes 
within the electronic medical records, which is a more general problem throughout the 
VA healthcare system. Anecdotally, those familiar with the VA system will often 
comment on the problem of clinicians copying and pasting notes, and the problem of 
casually written notes that possess inadequate relevant information. The concern is that 
there is too little relevant information and too much irrelevant information in the system – 
the signal to noise ratio is low. We encountered this problem repeatedly during our study.  




communication, thereby adversely affecting the quality of patient care throughout the 
system. Policies, incentives and better workflow designs need to be implemented at the 
VA to resolve the problem, perhaps on a hospital or even nation-wide basis.  
 
Options for a National Response to Study Results  
 
If the implications of our findings are interpreted more broadly, that is if we 
consider them as potentially representative of a phenomenon occurring on a national level 
rather than simply at the level of the West Haven VA, then we must address a vast and 
complex problem. In fact, the situation may be much worse for patients on a national 
level than it was in our study. For one, the West Haven VA is affiliated with the Yale 
academic medical network, so one might assume that the clinicians there are more up-to-
date on the current standards of care than clinicians at non-academic sites around nation. 
Also, the VA system offers relatively integrated and well-coordinated care, especially at 
the West Haven VA, where there is a primary care clinic devoted exclusively to patients 
with severe mental illnesses. But outside of the VA, mental healthcare in the US is often 
isolated from the rest of medicine. This makes the consultation process a challenge and 
may limit patient access to primary care physicians who monitor metabolic parameters. 
For example, community nephrologists, cardiologists, and renal transplant surgeons 
communicate regularly, but community psychiatrists are often outside of such quotidian 
communication and referral loops. Our study raises the question of whether this status 
quo should change. Indeed, psychiatrists are physicians first and psychiatrists second, 




integrate them with the greater medical community. Otherwise patients, like those in our 
study, will suffer from the effects of a poorly coordinated system.  
 How can we address the poor quality of metabolic monitoring and treatment on a 
national level? To begin, research such as this study must continue so that we can better 
understand how the current system of care operates and thus how it should change. 
Subsequently, leaders in mental health must accordingly formulate recommendations and 
guidelines to address the concerns raised by such research. The Mount Sinai guidelines 
are a good example of how this can be done. An absolutely critical step, and perhaps also 
the most challenging one, is to mobilize professional change. An effort is required by 
academic leaders, continuing medical education groups, and professional organizations – 
particularly the American Psychiatric Association – to drive awareness and 
implementation of guidelines. The effort and collaboration of non-psychiatric 
professional groups, such as the American Medical Association and American College of 
Physicians, is also needed. These groups must assist in bringing mental health care closer 
to the rest of medicine so that the problems of obesity and diabetes can be tackled in a 
coordinated fashion (among other issues). It is particularly important to link-up primary 
care clinicians and internal medicine specialists who focus on metabolic disorders with 
networks of psychiatrists and other MHCs.  
 In addition to leveraging the intrinsic incentives of patient care and 
professionalism, extrinsic financial incentives, tied to measurements, can be put in place 
to drive the adoption of guidelines and recommendations. Thus lobbying at various 
governmental levels, including Congress and the Center for Medicare and Medicaid 




health services. As performance measurements and performance-based incentives 
become more mainstream, and if they are effective at improving outcomes, one would 
hope that these tools would also be used to drive the adoption of guidelines and 
recommendations in the area of metabolic monitoring – and that appropriate 
reimbursement would be tied to such activities. Nevertheless, performance measurements 
alone, even in the absence of financial incentives, could drive change simply by drawing 
attention to the importance of metabolic monitoring. Yet to implement performance 
measurements on a large scale would require extensive improvements in information 
technology and communication throughout the fragmented mental health system, a 
scenario that appears unlikely in the near future in the absence of serious national 
healthcare reform.  
 It will also be important for the concepts of quality control and of total quality 
management to finally be absorbed and applied in a serious manner in American 
healthcare. Medicine has remained far too insular and has a tremendous amount to learn 
from other fields such as business operations management, manufacturing, and military 
systems control. It will be necessary for leaders within medicine to acquaint themselves 
with the concepts of quality management (94-98), and to retain experts from other fields 
such as business and manufacturing in order to improve the quality of healthcare delivery 
systems.  
 Setting aside broader issues of professional change and national healthcare 
reforms, there does exist one very direct solution that could rapidly change clinician 
behavior nationally, and it is based on what we have learned from clozapine regulation. 




count before the drug can be dispensed. A similar requirement to report biometrics (e.g. 
BMI and waist-size), in order for a pharmacy to dispense an antipsychotic, would rapidly 
alter psychiatric practice.  
 
Future Research Directions  
 
Beyond the content of this study, there is much work to be done. It would be 
useful to better understand how rates of documentation relate to actual behaviors, for 
example by comparing documentation of laboratory orders to laboratory transactions. It 
would also be interesting to determine if there are systemic differences between the 
documentation behavior of MHCs and PCCs, which one might suspect could be due to 
differences in professional culture, such as the high priority that MHCs may place on 
privacy relative to PCCs as a result of their training.  
 It is also critical to study whether the adoption of monitoring guidelines, such as 
those from Mount Sinai, actually improve outcomes (e.g. minimizes weight gains or 
decreases diabetes conversion rates). In order to drive individual and organizational 
change in the era of evidence-based medicine, proof that certain behaviors are linked to 
improved outcomes is critical. Then, if it is found to be true that metabolic monitoring by 
MHCs does indeed improve outcomes in areas such as weight gain and diabetes, we need 
in turn to better understand how to change clinician behavior such that guidelines will be 
adopted rapidly. An understanding of how to drive systemic change in clinical behavior 
might be found in the analysis of historical attempts to do so, or through cross-pollination 




quality management systems such as six-sigma (94-98). In addition to incorporating 
guidelines into practice and measuring their impact, such guidelines should be regularly 
updated to incorporate new tools as they emerge (e.g. promising genetic and metabolic 
tests, such as TNF-alpha, which were discussed in the Introduction).  
 Once a metabolic problem is recognized, the next step is intervention, and so 
researchers must also continue to create new interventions – and to verify the value of 
those that are used in current practice. Weight gain that results from antipsychotic 
treatment may require interventions that differ from those that are used for other types of 
weight gain. For example, one might ask: what are the relative benefits of changing 
antipsychotic dose, changing antipsychotic drug, consulting a nutritionist, or starting 
pharmacotherapy (e.g. metformin) for weight-gain? These and similar questions would be 
valuable to answer. Indeed, some researchers have already started to do so, a subject that 




In this cross-sectional study of 123 overweight or obese US veterans with 
psychotic disorders, 97% of whom were taking an antipsychotic, we determined with 
statistical significance that mental health clinicians identify, monitor and intervene for 
metabolic disorders, such as weight gain and hyperglycemia, at much lower rates than 
primary care physicians, and such rates are too low. We suspect that this is a problem of 
systemic, not individual, omission. Our findings are disconcerting given the growing 




second-generation antipsychotics – are linked to the development of metabolic 
dysfunction. In order to address this system-wide pattern of clinician behavior, which 
may be leading to serious adverse consequences for patients, we believe that 
organizational and operational systems must be changed, and that quality control systems 
must be instituted. Changes to the status quo ought to occur as soon as possible on both a 
local and national level so as to prevent harm to patients. Otherwise patients may 
continue to develop higher rates of preventable weight gain, diabetes, and metabolic 
syndrome – along with the life-threatening co-morbidities that are associated with such 









Table 1: Subject Race/Ethnicity (N=123) 
 Percent  
Not Documented 20%  
White 56%  
Hispanic 2%  
African-American 21%  
Other 1%  
 
 









Table 3: Age, Weight, BMI, and Number of Routine Office Visits (N=123) 
     











 Mean 54 218 32.4 3.4 15.6  
 Median 54 215 31.3 2.0 12.0  
 Mode 54 233 31.7 2.0 12.0  
 Minimum 31 137 25.0 1.0 1.0  
 Maximum 85 312 50.5 41.0 59.0  
 Range 54 175 25.5 40.0 58.0  
 
Standard 






Table 4: Subject Co-morbidities (N=123) 
 Percent
Diabetes Type I 1%






Obstructive Sleep Apnea 10%
Hypothyroidism 5%
Metabolic Syndrome 0%
Coronary Artery Disease 9%
Any Smoking (current) 51%
Any Alcohol Use (current) 21%
High Alcohol Use (current)      
(women >7 drinks per week; 






Table 5: Rates of Antipsychotic Therapy (N=123) 
 Percent  
Prescribed First Generation Antipsychotic 37%  
Prescribed Second Generation Antipsychotic 85%  
Prescribed at Least One Antipsychotic of 
Any Type 97%  
Prescribed Both a First and Second 
Generation Antipsychotic 25%  
Aripiprazole (Abilify) 10%  
Clozapine (Clozaril)  11%  
Olanzapine (Zyprexa) 22%  
Quetiapine (Seroquel) 24%  
Risperidone (Risperdal) 29%  
Ziprasidone (Geodon) 8%  
 
Table 6: Documentation of Biometrics in Visit Notes (N=123) 










Waist size  0% 0% - - -
Weight  85% 11% 0.66 0.82 <0.001
Height 59% 2% 0.48 0.66 <0.001






Table 7: Identification of Weight Issues Documented in Visit Notes (N=123)  










Identified weight as an issue in 
problem list 28% 13% 0.06 0.25 <0.005
Identified  weight as an issue in 
history 26% 15% 0.01 0.21 <0.015
Identified weight as an issue in 
assessment and plan 39% 17% 0.11 0.33 <0.001
Identified  weight as an issue in 
at least one of the following: 
problem list; history; assessment 
and plan 45% 28% 0.04 0.28 <0.005
Identified link between weight 
and antipsychotics 10% 12% -0.10 0.05 0.730
Identified weight loss as a 
therapy for a diagnosis other 






Table 8: Tests Ordered in Visit Notes (N=123) 










Blood glucose 50% 4% 0.36 0.55 <0.001
TSH  15% 4% 0.04 0.19 <0.005
Urinalysis  14% 0% 0.08 0.20 <0.001
Lipid panel  71% 2% 0.61 0.77 <0.001







Table 9: Interventions For Weight Loss Documented in Visit Notes (N=123)  










Made dietary recommendations to 
patient 57% 25% 0.20 0.43 <0.001
Made exercise recommendations to 
patient 46% 22% 0.12 0.35 <0.001
Made exercise and dietary 
recommendations to patient 42% 19% 0.12 0.35 <0.001
Ordered at least one referral for weight 
management 21% 3% 0.10 0.26 <0.001
Considered or ordered 
pharmacotherapy for weight loss 1% 0% -0.01 0.02 0.158
Considered or ordered change of 
antipsychotic medication due to weight 2% 4% -0.06 0.03 0.764
Considered or ordered change of 
antipsychotic dose due to weight  2% 5% -0.07 0.02 0.846
Considered or ordered change of 
antipsychotic medication and/or dose 
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